TerminatedNCT06635135

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

Medication studyAges 18–64Multiple countries

The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 64 years.

Listed locations: Little Rock and 94 more locationsSee all locations and recruitment
Study phase: Phase 3

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: September 19, 2024

Recruitment status: Terminated
Enrollment listed in the registry: 47
Sponsor: Janssen Research & Development, LLC
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 3
Locations: United States, France, Belgium, ...
Age range: From 18 Years to 64 Years
Official registry ID: NCT06635135
Official title: Show the full official title
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

Get this study by email

Recruitment & locations

Terminated

Little Rock, United States · Encino, United States · Newport Beach, United States

84 more locations

Orange, United States
Redlands, United States
San Diego, United States
Doral, United States
Miami, United States
North Miami Beach, United States
Orlando, United States
Tampa, United States
Atlanta, United States
Chicago, United States
Skokie, United States
Towson, United States
Boston, United States
Columbia, United States
Albuquerque, United States
Brooklyn, United States
Mount Kisco, United States
Cincinnati, United States
Independence, United States
Tulsa, United States
Plymouth Meeting, United States
North Charleston, United States
DeSoto, United States
Friendswood, United States
Clinton, United States
St. George, United States
Buenos Aires, Argentina
Córdoba, Argentina
Alken, Belgium
Assebroek, Belgium
Brussels, Belgium
Oudenaarde, Belgium
Sint-Niklaas, Belgium
Campinas, Brazil
São Bernardo do Campo, Brazil
Rousse, Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Vratsa, Bulgaria
Besançon, France
Montpellier, France
Nantes, France
Sotteville-lès-Rouen, France
Toulon, France
Berlin, Germany
Chemnitz, Germany
Frankfurt am Main, Germany
Hamburg, Germany
Hennigsdorf, Germany
Münster, Germany
Rosenheim, Germany
Schwerin, Germany
Athens, Greece
Heraklion, Greece
Ioannina, Greece
Thessaloniki, Greece
León, Mexico
Mexico City, Mexico
México, Mexico
Monterrey, Mexico
Bydgoszcz, Poland
Grudziądz, Poland
Leszno, Poland
Lublin, Poland
Poznan, Poland
Suchy Las, Poland
Warsaw, Poland
Wroclaw, Poland
Bucharest, Romania
Craiova, Romania
Focşani, Romania
Galați, Romania
Sibiu, Romania
Bilbao, Spain
Córdoba, Spain
Granada, Spain
Madrid, Spain
Málaga, Spain
Palma, Spain
Pamplona, Spain
Ponferrada, Spain
Zaragoza, Spain
Istanbul, Türkiye
Türkiye

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen Research & Development, LLC.

Does this study involve medication?

Yes. The study involves medication, including Aticaprant.

Who can participate?

Listed age limits: 18 years to 64 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies